SCHEMBL5513433

SCHEMBL5513433

CC(C)Cc1ccnc(C(=O)O)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
ALDH1A1 P00352 3/20 0.50
KDM6B O15054 1/20 0.50
TET3 O43151 1/20 0.50
KDM4A O75164 1/20 0.50
BBOX1 O75936 1/20 0.50
MAPT P10636 1/20 0.50
KDM5A P29375 1/20 0.50
KDM5C P41229 1/20 0.50
ASPH Q12797 1/20 0.50
KDM4D Q6B0I6 1/20 0.50
TET2 Q6N021 1/20 0.50
ALKBH5 Q6P6C2 1/20 0.50
KDM7A Q6ZMT4 1/20 0.50
KDM8 Q8N371 1/20 0.50
TET1 Q8NFU7 1/20 0.50
EGLN2 Q96KS0 1/20 0.50
FTO Q9C0B1 1/20 0.50
EGLN1 Q9GZT9 1/20 0.50
KDM4C Q9H3R0 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13621658 0.85 NR3C2 (0.44) PTGS1PTGS2LMNACYP2C9AKR1C3
SCHEMBL5525023 0.83 KDM4E (0.47) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL24252514 0.82 ALDH1A1 (0.41) KDM4EALDH1A1MAPTPTGS1PTGS2
SCHEMBL15858773 0.82 ACACB (0.51) KDM4EALDH1A1KDM6BMAPTKDM5C
SCHEMBL221963 0.80 ALDH1A1 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL30281240 0.80 ALDH1A1 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL15562032 0.80 HSD17B10 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL743556 0.80 KDM4E (0.47) KDM4EALDH1A1KDM6BTET3KDM4A
SCHEMBL15562033 0.80 HSD17B10 (0.55) KDM4EALDH1A1KDM6BTET3KDM4A
Hydrochloric Acid SCHEMBL968208 0.79 ALDH1A1 (0.53) KDM4EALDH1A1KDM6BTET3KDM4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230158025-A1 GALACTOKINASE INHIBITORS NATIONAL INSTITUTES OF HEALTH 2023-05-25 US disclosed
US-9799839-B2 Organometallic compound and organic light-emitting diode comprising the same Samsung Diplay Co., Ltd. (KR) 2017-10-24 US disclosed
US-9799839-B2 Organometallic compound and organic light-emitting diode comprising the same Samsung Diplay Co., Ltd. (KR) 2017-10-24 US disclosed
US-9691992-B2 Organic light-emitting diode SAMSUNG DISPLEY CO., LTD. (KR) 2017-06-27 US disclosed
US-9691992-B2 Organic light-emitting diode SAMSUNG DISPLEY CO., LTD. (KR) 2017-06-27 US disclosed
US-9691992-B2 Organic light-emitting diode SAMSUNG DISPLEY CO., LTD. (KR) 2017-06-27 US disclosed
US-20140209880-A1 ORGANIC LIGHT-EMITTING DIODE SAMSUNG DISPLAY CO., LTD. (KR) 2014-07-31 US disclosed
US-20140209880-A1 ORGANIC LIGHT-EMITTING DIODE SAMSUNG DISPLAY CO., LTD. (KR) 2014-07-31 US disclosed
US-20140209880-A1 ORGANIC LIGHT-EMITTING DIODE SAMSUNG DISPLAY CO., LTD. (KR) 2014-07-31 US disclosed
US-20140183467-A1 ORGANOMETALLIC COMPOUND AND ORGANIC LIGHT-EMITTING DIODE COMPRISING THE SAME SAMSUNG DISPLAY CO., LTD. (KR) 2014-07-03 US disclosed
CN-1315859-C Lincomycin derivatives possessing antibacterial activity VICURON PHARM INC (US) 2007-05-16 CN disclosed
US-7199105-B2 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS, INC. (US) 2007-04-03 US disclosed
US-7164011-B2 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS, INC. (US) 2007-01-16 US disclosed
EP-1654268-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2006-05-10 EP disclosed
CN-1681832-A Lincomycin derivatives possessing antibacterial activity VICURON PHARM INC (US) 2005-10-12 CN disclosed
EP-1529052-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY Vicuron Pharmaceuticals, Inc. (US) 2005-05-11 EP disclosed
WO-2005007665-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS INC. (US) 2005-01-27 WO disclosed
US-20040230046-A1 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. 2004-11-18 US disclosed
US-20040116690-A1 Lincomycin derivatives possessing antibacterial activity VICURON PHARMACEUTICALS INC. 2004-06-17 US disclosed
WO-2004016632-A2 LINCOMYCIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY VICURON PHARMACEUTICALS, INC. (US) 2004-02-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040230046-A1 Lincomycin derivatives possessing antibacterial activity NRDC, NISCH, CLSPN KDM4E 3921/4885ALDH1A1 2737/4885KDM6B 4020/4885
US-20230158025-A1 GALACTOKINASE INHIBITORS GALK1, GCK, GCKR KDM4E 2218/4885ALDH1A1 3139/4885KDM6B 2216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.